X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3666) 3666
Publication (411) 411
Book Review (41) 41
Book Chapter (18) 18
Conference Proceeding (8) 8
Dissertation (4) 4
Streaming Video (4) 4
Reference (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2362) 2362
animals (2130) 2130
glucagon-like peptide-1 (1929) 1929
humans (1883) 1883
male (1361) 1361
biochemistry & molecular biology (955) 955
glucose (942) 942
glucagon (927) 927
mice (890) 890
endocrinology & metabolism (836) 836
rats (836) 836
insulin (827) 827
diabetes (822) 822
peptides (796) 796
glucagon-like peptide 1 (775) 775
type 2 diabetes (698) 698
female (669) 669
glp-1 (666) 666
pharmacology & pharmacy (614) 614
glucagon-like peptide 1 - metabolism (533) 533
diabetes mellitus, type 2 - drug therapy (530) 530
insulin - metabolism (489) 489
obesity (456) 456
secretion (451) 451
glucagon-like peptide-1 receptor (444) 444
physiology (404) 404
diabetes mellitus (402) 402
blood glucose - metabolism (399) 399
middle aged (384) 384
adult (382) 382
insulin secretion (379) 379
physiological aspects (373) 373
analysis (359) 359
metabolism (358) 358
research (336) 336
dextrose (334) 334
insulin - blood (334) 334
rodents (330) 330
digestive, oral, and skin physiology (319) 319
insulin resistance (316) 316
hypoglycemic agents - therapeutic use (315) 315
expression (313) 313
amino acid sequence (310) 310
mice, inbred c57bl (309) 309
endocrine system (306) 306
hypoglycemic agents - pharmacology (305) 305
glucagon-like peptide 1 - blood (304) 304
cell biology (301) 301
proteins (298) 298
peptides - pharmacology (292) 292
receptor (285) 285
medicine (283) 283
diabetes mellitus, type 2 - metabolism (281) 281
cell line (264) 264
exendin-4 (264) 264
hormones (262) 262
molecular sequence data (262) 262
insulin-secretion (260) 260
article (254) 254
hormones, hormone substitutes, and hormone antagonists (254) 254
signal transduction (252) 252
multidisciplinary sciences (251) 251
receptors, glucagon - metabolism (251) 251
research article (250) 250
food-intake (246) 246
glucagon-like peptide 1 - pharmacology (246) 246
glucose metabolism (239) 239
gastric-inhibitory polypeptide (238) 238
pancreas (238) 238
rats, sprague-dawley (238) 238
glycemic control (236) 236
health aspects (233) 233
liraglutide (232) 232
glucose - metabolism (228) 228
nutrition & dietetics (226) 226
insulin-secreting cells - metabolism (222) 222
glucose tolerance test (221) 221
body weight (219) 219
exenatide (218) 218
gene expression (214) 214
glucagon-like peptide 1 - analogs & derivatives (206) 206
peptides - chemistry (205) 205
incretin (204) 204
glucagon - metabolism (203) 203
rats, wistar (202) 202
hyperglycemia (200) 200
homeostasis (196) 196
activation (195) 195
aged (194) 194
science (191) 191
biochemistry (188) 188
in-vivo (188) 188
diabetes mellitus, type 2 - blood (187) 187
endocrinology (186) 186
blood glucose - drug effects (185) 185
in-vitro (184) 184
diet (183) 183
insulin-resistance (183) 183
biology (181) 181
dependent insulinotropic polypeptide (178) 178
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3667) 3667
Japanese (33) 33
Chinese (5) 5
French (2) 2
German (1) 1
Korean (1) 1
Romanian (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9683, pp. 39 - 47
Summary Background Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight... 
Internal Medicine | METFORMIN | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | SULFONYLUREA | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | HUMAN GLP-1 ANALOG | BETA-CELL MASS | TREATED PATIENTS | ACUTE-PANCREATITIS | WEIGHT | Nausea - chemically induced | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Dose-Response Relationship, Drug | Glucagon-Like Peptide 1 - agonists | Injections, Subcutaneous | Female | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Peptides - chemistry | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glucagon-Like Peptide 1 - chemistry | Linear Models | Logistic Models | Treatment Outcome | Hypoglycemic Agents - chemistry | Blood Glucose - drug effects | Analysis of Variance | Venoms - therapeutic use | Venoms - chemistry | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Hypoglycemic agents | Dosage and administration | Drug therapy | Molecular structure | Clinical trials | Diabetes | Clinical medicine | Apoptosis | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes, ISSN 0012-1797, 03/2003, Volume 52, Issue 3, pp. 751 - 759
The rapid degradation of native glucagon-like peptide 1 (GLP-1) by dipeptidyl peptidase-IV (DPP-IV) has fostered new approaches for generation of... 
GLP-1, glucagon-like peptide 1 | CHO, Chinese hamster ovary | GLP-1R, GLP-1 receptor | DAC, drug affinity complex | GIP, glucose-dependent insulinotropic peptide | AUC, area under the curve | HSA, human serum albumin | DPP-IV, dipeptidyl peptidase-IV | DIABETES-MELLITUS | DB/DB MICE | SERUM-ALBUMIN | IN-VIVO | ENDOCRINOLOGY & METABOLISM | DEPENDENT INSULINOTROPIC POLYPEPTIDE | BETA-CELL MASS | GASTRIC-INHIBITORY POLYPEPTIDE | IMPROVED GLUCOSE-TOLERANCE | FATTY ZUCKER RATS | ALBUMIN-BINDING | Diabetes Mellitus - blood | Dipeptidyl Peptidase 4 - metabolism | Glucagon-Like Peptide 1 | Hypoglycemic Agents - metabolism | Protein Precursors - chemistry | Humans | Maleimides - pharmacology | Body Weight - drug effects | RNA, Messenger - analysis | Glucagon - agonists | Peptides - metabolism | Transfection | Glucagon - chemistry | Maleimides - metabolism | Serum Albumin - chemistry | Cyclic AMP - metabolism | CHO Cells | Fibroblasts - metabolism | Protein Precursors - agonists | Receptors, Glucagon - genetics | Recombinant Proteins - metabolism | Cricetinae | Glucose Tolerance Test | Peptide Fragments - metabolism | Receptors, Glucagon - deficiency | Blood Glucose - analysis | Peptides - chemistry | Mice, Inbred C57BL | Diabetes Mellitus - drug therapy | Receptors, Glucagon - metabolism | Proinsulin - genetics | Hypoglycemic Agents - chemistry | Hypoglycemic Agents - pharmacology | Mice, Knockout | Peptides - pharmacology | Protein Precursors - metabolism | Peptide Fragments - chemistry | Animals | Glucagon-Like Peptide-1 Receptor | Peptide Fragments - agonists | Glucagon - metabolism | Mice | Maleimides - chemistry | Serum Albumin - metabolism | Type 2 diabetes | Physiological aspects | Care and treatment | Glucagon
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 09/2014, Volume 136, Issue 37, pp. 12848 - 12851
Glucagon-like peptide-1 (GLP-1) is a natural agonist for GLP-1R, a G protein-coupled receptor (GPCR) on the surface of pancreatic β cells. GLP-1R agoinsts are... 
DESIGN | INHIBITION | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | STABILITY | PROTEIN-PROTEIN INTERACTIONS | COUPLED RECEPTORS | AMINO-ACID RESIDUES | AGONISTS | CHEMISTRY, MULTIDISCIPLINARY | HELIX MIMICRY | Type 2 diabetes | Care and treatment | Peptides | Glucagon | Analysis | Residues | Surgical implants | Biomedical materials | In vivo testing | Surface chemistry | In vivo tests | Biocompatibility | Strategy | Communication
Journal Article
Nature, ISSN 0028-0836, 06/2017, Volume 546, Issue 7657, pp. 254 - 258
Journal Article
by Hernandez, Adrian F and Green, Jennifer B and Janmohamed, Salim and D'Agostino, Ralph B and Granger, Christopher B and Jones, Nigel P and Leiter, Lawrence A and Rosenberg, Anne E and Sigmon, Kristina N and Somerville, Matthew C and Thorpe, Karl M and McMurray, John J V and Del Prato, Stefano and Del Prato, Stefano and McMurray, John J.V and D'Agostino, Ralph B and Granger, Christopher B and Hernandez, Adrian F and Janmohamed, Salim and Leiter, Lawrence A and Califf, Robert M and Holman, Rury and DeMets, David and Riddle, Matthew and Goodman, Shaun and McGuire, Darren and Alexander, Karen and Devore, Adam and Melloni, Chiara and Patel, Chetan and Kong, David and Bloomfield, Gerald and Roe, Matthew and Tricoci, Pierluigi and Harrison, Rob and Lopes, Renato and Mathews, Robin and Mehta, Rajendra and Schuyler Jones, William and Vemulapalli, Sreekanth and Povsic, Thomas and Eapen, Zubin and Dombrowski, Keith and Kolls, Brad and Jordan, Dedrick and Ambrosy, Andrew and Greene, Stephen and Mandawat, Aditya and Shavadia, Jay and Cooper, Lauren and Sharma, Abhinav and Guimaraes, Patricia and Friedman, Daniel and Wilson, Matt and Endsley, Patricia and Gentry, Tracy and Collier, Jeannie and Perez, Kathleen and James, Kourtnei and Roush, Jennifer and Pope, Connie and Howell, Christina and Johnson, Megan and Bailey, Matt and Cole, Joanna and Akers, Teresa and Vandyne, Beth and Thomas, Betsy and Rich, Jenny and Bartone, Susan and Beaulieu, Gail and Brown, Kim and Chau, Tuan and Christian, Tamra and Coker, Rebecca and Greene, Deb and Haddock, Trevorlyn and Jenkins, Wendy and Haque, Ghazala and Marquess, Marsha and Pesarchick, Jean and Rethaford, Renee and Stone, Allegra and Al Kawas, Firas and Anderson, Michelle and Enns, Robert and Sinay, Isaac and Mathieu, Chantal and Yordanov, Victor and Hramiak, Irene and Haluzik, Martin and Galatius, Søren and Guerci, Bruno and Nauck, Michael and Migdalis, Ilias and Tan, Choon Beng Kathryn and Kocsis, Gyozo and Giaccari, Andrea and Lee, Moon Kyu and Muñoz, Ernesto German Cardona and ... and Harmony Outcomes committees and investigators and Harmony Outcomes Comm Investigator
The Lancet, ISSN 0140-6736, 10/2018, Volume 392, Issue 10157, pp. 1519 - 1529
Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular... 
MEDICINE, GENERAL & INTERNAL | RISK | METAANALYSIS | MELLITUS | SAFETY | RECEPTOR AGONISTS | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptide 1 - administration & dosage | Glucagon-Like Peptide 1 - analogs & derivatives | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Stroke - etiology | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Aged | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Myocardial Infarction - etiology | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide 1 - therapeutic use | Myocardial infarction | Diabetic retinopathy | Heart attacks | Peptides | Glucagon | Medical services | Clinical trials | Cardiovascular disease | Thyroid gland | Incidence | Thyroid carcinoma | Randomization | Motivation | Hemoglobin | Diuretics | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Thyroid | Cerebral infarction | Stroke | Diabetes mellitus | Pancreatitis | Health risks | Risk reduction | Disease control | Patients | Organic chemistry | Interactive systems | Pancreatic cancer | Fatalities | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment
Journal Article
Diabetes, ISSN 0012-1797, 08/2018, Volume 67, Issue 8, pp. 1538 - 1548
Glucagon-like peptide 1 receptor (GLP-1R) agonists are U.S. Food and Drug Administration-approved weight loss drugs. Despite their widespread use, the sites of... 
GLUCOSE-HOMEOSTASIS | ENERGY-EXPENDITURE | VISCERAL ILLNESS | FOOD-INTAKE | NUCLEUS | ENDOCRINOLOGY & METABOLISM | GLP-1 RECEPTORS | MICE | BRAIN ACTIVATION | AREA POSTREMA | AGONIST | Neurons - pathology | Vesicular Glutamate Transport Protein 2 - chemistry | Obesity - drug therapy | Diet, High-Fat - adverse effects | Glucagon-Like Peptide-1 Receptor - chemistry | Male | Green Fluorescent Proteins - genetics | Nerve Net - drug effects | Weight Loss - drug effects | Appetite Depressants - therapeutic use | Recombinant Fusion Proteins - metabolism | Glucagon-Like Peptide-1 Receptor - genetics | Glucagon-Like Peptide-1 Receptor - metabolism | Nerve Tissue Proteins - chemistry | Obesity - etiology | Neurons - metabolism | GABAergic Neurons - metabolism | Hypothalamus - drug effects | Green Fluorescent Proteins - chemistry | Neurons - drug effects | Vesicular Glutamate Transport Protein 2 - genetics | Hypoglycemic Agents - therapeutic use | Green Fluorescent Proteins - metabolism | Nerve Tissue Proteins - agonists | Vesicular Glutamate Transport Protein 2 - metabolism | GABAergic Neurons - drug effects | Mice, Transgenic | Energy Intake - drug effects | Hypothalamus - pathology | Random Allocation | Recombinant Fusion Proteins - chemistry | Nerve Tissue Proteins - genetics | Mice, Knockout | Obesity - metabolism | Obesity - pathology | Nerve Tissue Proteins - metabolism | Animals | Hypothalamus - metabolism | Vesicular Inhibitory Amino Acid Transport Proteins - metabolism | Vesicular Inhibitory Amino Acid Transport Proteins - chemistry | Liraglutide - therapeutic use | Vesicular Inhibitory Amino Acid Transport Proteins - genetics | Nerve Net - metabolism | Genes, Reporter - drug effects | Glucagon-Like Peptide-1 Receptor - agonists | Appetite | Glucagon | Body weight | Dosage and administration | Research | Gene expression | Health aspects | Liraglutide | Index Medicus | Abridged Index Medicus | 0707 | Obesity Studies
Journal Article
Peptides, ISSN 0196-9781, 02/2018, Volume 100, pp. 202 - 211
•Combined activation of peptide hormone receptors has therapeutic promise for diabetes.•Exendin-4/xenin-8-Gln is an enzymatically stable and biological active... 
Hybrid | Xenin | Glucagon-like-peptide-1 (GLP-1) | Glucose-dependent insulinotropic polypeptide (GIP) | Glucose homeostasis | Insulin secretion | OBESE-DIABETIC OB/OB | GLP-1 RECEPTOR AGONISTS | DB/DB MICE | BIOCHEMISTRY & MOLECULAR BIOLOGY | POSTPRANDIAL GLUCOSE | IV-RESISTANT | BETA-CELL FUNCTION | GLUCAGON-LIKE PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | PHARMACOLOGY & PHARMACY | GASTROINTESTINAL HORMONES | DEPENDENT INSULINOTROPIC POLYPEPTIDE | GASTRIC-INHIBITORY POLYPEPTIDE | Glucagon-Like Peptide 1 - administration & dosage | Humans | Diet, High-Fat - adverse effects | Diabetes Mellitus, Type 2 - metabolism | Exenatide - chemistry | Neurotensin - chemistry | Hypoglycemic Agents - administration & dosage | Glucagon - chemistry | Neurotensin - administration & dosage | Disease Models, Animal | Glucagon-Like Peptide 1 - chemistry | Hypoglycemic Agents - chemistry | Gastric Inhibitory Polypeptide - administration & dosage | Blood Glucose - drug effects | Insulin - metabolism | Animals | Gastric Inhibitory Polypeptide - chemistry | Insulin-Secreting Cells - drug effects | Glucose - metabolism | Exenatide - administration & dosage | Glucagon - metabolism | Mice | Diabetes Mellitus, Type 2 - pathology | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Type 2 diabetes | Blood cholesterol | Low density lipoproteins | Body weight | Homeostasis | Glucose | Cholecystokinin | Insulin | Dextrose | Glutamine
Journal Article
Nature Medicine, ISSN 1078-8956, 12/2014, Volume 21, Issue 1, pp. 27 - 36
Journal Article